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What’s new? 
Fatty acid synthase (FASN) has been regarded as marker of malignancy and as cancer drug target. 
Being overexpressed in cancer it regulates oncogenic de-novo-lipogenesis. There is general 
agreement that normal cells are FASN-negative. We now demonstrate that FASN is overexpressed in 
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the ovarian system when cells reveal high growth rates, which correlates with distinctive lipid 
profiles, irrespective of their state of malignancy/differentiation/senescence. Thus, FASN represents 
a metabolic marker of ovarian cell proliferation rather than of cancer.
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Abstract 
Ovarian cancer (OC) is caused by genetic aberrations in networks that control growth and survival. 
Importantly, aberrant cancer metabolism interacts with oncogenic signaling providing additional drug 
targets. Tumors overexpress the lipogenic enzyme fatty acid synthase (FASN) and are inhibited by 
FASN-blockers, whereas normal cells are FASN-negative and FASN-inhibitor-resistant. Here we 
demonstrate that this holds true when ovarian/oviductal cells reside in their autochthonous tissues, 
whereas in culture they express FASN and are FASN-inhibitor-sensitive. Upon subculture, non-
malignant cells cease growth, express senescence-associated-β-galactosidase, lose FASN and become 
FASN-inhibitor-resistant. Immortalized ovarian/oviductal epithelial cell lines – although resisting 
senescence – reveal distinct growth activities, which correlate with FASN-levels and FASN-drug-
sensitivities. Accordingly, ectopic FASN stimulates growth in these cells. Moreover, FASN-levels and 
lipogenic activities affect cellular lipid composition as demonstrated by thin-layer chromatography. 
Correlation between proliferation and FASN-levels was finally evaluated in cancer cells such as HOC-
7, which contain subclones with variable differentiation/senescence and corresponding FASN-
expression/FASN-drug-sensitivity. Interestingly, senescent phenotypes can be induced in parental 
HOC-7 by differentiating agents. In OC cells, FASN-drugs induce cell cycle-blockade in S and/or G2/M 
and stimulate apoptosis, whereas in normal cells they only cause cell cycle-deceleration without 
apoptosis. Thus normal cells, although growth-inhibited, may survive and recover from FASN-
blockade, whereas malignant cells get extinguished. FASN-expression and FASN-drug-sensitivity are 
directly linked to cell growth and correlate with transformation/differentiation/senescence only 
indirectly. FASN is therefore a metabolic marker of cell proliferation rather than a marker of 
malignancy and is a useful target for future drug development. 
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Introduction 
For the last thirty years cancer researchers paid most attention to the discovery of genetic alterations 
in oncogenic and tumor suppressor genes, which function as regulators of growth, migration and 
apoptosis.
1
 This led to the identification of cancer drug targets and corresponding therapeutics, 
which are added to the armamentarium in the fight against cancer. In the case of ovarian cancer 
(OC), however, this approach has yielded only limited benefits.
2
 Thus, especially for advanced OC, 
novel approaches are urgently needed. Notably, it has been known for decades that cancer cells 
reveal alterations in their metabolism such as aerobic glycolysis, acidosis, glutamine consumption 
and hypoxia.
3,4
 Recently, it has been recognized that metabolic pathways closely interact with 
oncogenic networks and that altered oncogenes and tumor suppressor genes directly affect cancer 
cell metabolism.
5
 For instance, the proto-oncogene c-Myc crosstalks with hypoxia-inducible factors 
enabling continued proliferation despite tissue hypoxia
6
 and spurs aerobic glycolysis and acidosis.
7
 
Cancer cells not only have high demands for bioenergy for cell division provided by catabolic 
pathways, they also depend on supply with biomolecules for building new cell material. Both 
requirements are met by glycolytic breakdown of carbohydrates, which not only provide moderate 
levels of ATP, but also deliver components for biosynthesis of macromolecules.
8
  In addition, cancer 
cells have been found to reveal hyperactivation of de novo (phospho)lipid synthesis, which is 
required for production of biomembranes.
9
 Thus, fatty acid synthase (FASN), the key enzyme for 
production of palmitic acid, which is the precursor of all lipids,
10
 is overexpressed in cancer cells, 
confers chemoresistance and correlates with tumor progression.
11-13
 In contrast, most normal cells 
(except hepatocytes, adipocytes) are essentially negative for FASN.
9
 Interestingly, data from 
metabolic radiolabeling indicate that senescent cells, unlike proliferating cells, reveal reduced de 
novo synthesis of phospholipids (PLs), but elevated levels of cholesterol and of unsaturated fatty 
acids
14
 suggesting changes of lipid metabolism. Notably, high levels of EGFR-, HER2- or AKT-
oncoprotein correlate with FASN overexpression/phosphorylation corroborating the link between 
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oncogene pathways and metabolic systems.
15-17
 Most importantly, blunting FASN-action arrests 
growth and induces death in cancer cells prompting the development of FASN-inhibitory compounds 
for cancer treatment.
18
 Thus, FASN represents a cancer biomarker and a promising target. It is 
therefore tempting to speculate that FASN-targeting will represent a novel anti-metabolic approach 
to be added to the armamentarium against OC.  
In contrast to the widely accepted concept that normal cells are negative for FASN and insensitive 
against FASN-blockers, we report here that normal non-malignant human ovarian surface epithelial 
cells and oviduct secretory epithelial cells, from which high-grade serous OCs arise, do produce high 
amounts of FASN and depend on it for growth in culture. However, during ageing in culture, they 
downregulate FASN and lose responsiveness to FASN-inhibitors. Correspondingly, in the body, 
healthy epithelia from the ovarian surface and from the fimbriae of the oviduct were quiescent and 
FASN-negative, whereas cancer tissues expressed FASN according to their growth activity. Using 
FASN-targeting drugs we demonstrate that FASN-inhibition impairs cancer cells causing cell cycle 
block and apoptosis in vitro, whereas in healthy proliferating cells they only reduce cell cycle 
progression. Moreover, characteristic differences in the lipid profiles of non-malignant young and 
senescent cells and after FASN-inhibition in young cells were observed. In summary, our data 
demonstrate that FASN is associated with cell proliferation rather than with malignancy and that 
FASN is a useful cancer target since quiescent normal cells usually lack it and the few dividing normal 
cells, being positive for it, are not eliminated by the FASN-drugs. 
Materials and Methods 
Cell Culture and Drugs 
OC cell lines A2774, A2780, A2780-ADR (M.Krainer, Medical University Vienna, Austria), HEY, HOC-7 
(R.N.Buick, University of Toronto, Canada), HOC-7 monoclonal derivatives N1-N3, D1-D3,
19
 TR170 
(B.T.Hill, Imperial Cancer Research Fund, London, UK), OVCAR-3, PA-1, SKOV3 (ATCC, Manassas, VA) 
were maintained in alpha-MEM, RPMI1640 or DMEM, respectively, and were subcultured for ≤20 
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passages. Immortalized human fallopian tube secretory epithelial cells engineered to overexpress 
hTERT together with either SV40T/t (FT33-TAg) or p53 shRNA plus mutant CDK4 (FT237-shp) 
(R.Drapkin, Dana-Farber Cancer Institute, Boston, MA)
20
 were cultivated in DMEM/Ham’sF12(1:2). 
Non-malignant human ovarian surface epithelial cells IOSE-80, IOSE-364, IOSE-386 (N.Auersperg, 
Canadian Ovarian Tissue Bank, British Columbia Cancer Research Centre, Canada) revealing extended 
but finite life span due to exogenous expression of SV40T/t
21
 were grown in 
Medium199/MCDB105(1:2). Primary human ovarian surface epithelial cells (OSE; Innoprot, Derio, 
Spain) were cultivated in OSE-medium containing 1%OSE-supplement and 100IU(µg)/ml penicillin-
streptomycin (Innoprot). For adherence of OSE, surfaces were pre-coated with 2µg poly-L-lysine/cm
2
 
according to manufacturer’s protocols. Normal human foreskin fibroblasts (CRL-2522, ATCC) were 
cultured in alpha-MEM. Media, except OSE-medium, were supplemented with 5 or 10% fetal calf 
serum (FCS), 100IU(µg)/ml penicillin-streptomycin and 2mM glutamine (Gibco, Karlsruhe, Germany). 
Cells were maintained at 37°C, 5%CO2 and 95%humidity and were tested for absence of 
viral/bacterial/fungal/mycoplasmal infection (Venor GeM, Minerva Biolabs, Berlin, Germany). The 
species origins were proven by species-PCR, and cell line identities were examined by fluorescent 
nonaplex-PCR of short tandem repeat markers (DSMZ, Braunschweig, Germany). FASN-inhibitors C75 
(racemic mixture of (-)- and (+)-enantiomers, Sigma, St. Louis, MO), (-)-C75, (+)-C75 (F.G.Hegardt, 
D.Serra, Barcelona, Spain)
22
 and G28UCM (R.Colomer, M.L.López Rodríguez, Madrid, Spain)
23,24
 were 
dissolved in DMSO and diluted 1:500 or 1:1,000 in media before use. Cells were usually treated with 
racemic C75 except one experiment, in which racemic C75 was compared with the enantiomers. 
DNA Constructs and Transfections 
Full-length wild-type human FASN cDNA (NM004104) cloned into pcDNA3 was provided by J.-T.Zhang 
(Indiana University School of Medicine, Indianapolis, IN).
25
 For transfection, 8x10
5
 senescent 
(passage24–26) IOSE-80 cells were plated in 35mm tissue culture dishes and further processed as 
described.
26
 Transiently transfected, polyclonal cell populations were subjected to BrdU-labeling or 
to Western blot-analysis (see below). For stable transgene expression, transfectants were exposed to 
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300µg/mlG418 (Merck KGaA, Darmstadt, Germany) for ≥3 weeks. Cells were then trypsinized and 
counted under the microscope. 
Cell Proliferation 
Cells (250-4,500/well, 96-well plate) attached overnight before media containing 5%FCS or 1%OSE-
supplement±drugs were added. Cell numbers were estimated using a formazan-dye-assay 
(Biomedica, Vienna, Austria). 
DNA Synthesis 
Incorporation of 5-bromo-2'-deoxyuridine (BrdU) into nascent DNA-strands was used for 
determination of DNA-synthesis using the Cell Proliferation ELISA, BrdU (colorimetric) from Roche 
(Penzberg, Germany). IOSE-80, IOSE-364, IOSE-386 cells  (1500/well) or FT33-TAg, FT237-shp 
(6000/well) were grown in 96-well plates in media containing 5 or 10%FCS for 48h followed by a 6h-
incubation in BrdU-labeling solution at 37°C, 5%CO2, 95%humidity. Subsequent immunodetection 
was performed according to manufacturer’s protocols. 
Western Blotting 
Cells plated in media containing 5%FCS or 1%OSE-supplement were treated with solvent 
(≤0.2%DMSO) in the absence/presence of C75 or G28UCM, or with DMSO alone at  doses of 1.5% or 
1.8%. At this high concentrations DMSO acts as differentiation-inducer.
27,28
 After cell lysis proteins 
were subjected to SDS–PAGE, blotted and immunostained as described
29
 using: anti-FASN (BD 
Biosciences, Franklin Lakes, NJ, 1:500), anti-β-gal (Santa Cruz Biotechnology, Santa Cruz, CA, 1:200), 
anti-PARP-1 (1:500), anti-α,β-tubulin (both from Cell Signaling Technology, Boston, MA, 1:1,000), and 
anti-actin (I-19, Santa Cruz Biotechnology, 1:1,000). Secondary antibodies were peroxidase-labelled 
donkey-anti-rabbit (Promega, Madison, WI), donkey-anti-goat or chicken anti-mouse IgG (both from 
Santa Cruz Biotechnology) at 1:15,000. Detection was by enhanced chemiluminescence. 
In-situ Staining for Senescence-Associated-β-Galactosidase (SA-β-gal) 
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See ‘Supplementary Information’ 
Lipid Extraction 
Published protocols were used.
30
 Briefly, 10
5
–10
6
 suspended cells were washed 3x with PBS 
containing 0.5mM EDTA and 0.01% butylated hydroxytoluene (antioxidants), centrifuged (5000xg,  
5min), resuspended in 100µl H2O before 1.6ml CHCl3:MeOH[70:30(v/v)] was added, sonicated for 
1min and incubated on ice for 30min. Then, 0.4ml of 0.7M aqueous formic acid was added, vortexed 
and centrifuged (5000xg, 5min) to separate lower organic phase containing most neutral- and 
phospholipids from upper phase. Lipids from lower phase were vacuum dried, redissolved in 50µl 
CHCl3:MeOH (70:30) and stored at ≤-20°C. 
Thin-layer Chromatography 
Plates (ALUGRAM

 Nano-SIL-G, Macherey-Nagel, Düren, Germany) were developed full-length 
(10cm) with pure hexane, rotated by 90° and edeveloped full-length, then dried on a heating-plate 
(150°C, 20min) and 8-10µl of lipid extracts were applied. Plates were developed using methyl-
acetate:1-propanol:CHCl3:methanol:0.25%KCl[25:25:25:10:9(v/v/v/v/v)]
31
 until 4.5cm from origin for 
separation of PLs, dried by hot air (1-2min) and developed again using hexane:diethyl ether:acetic 
acid[80:20:1.5(v/v/v)]
32
 until 9.5cm from origin for separation of neutrallipids. Plates were redried, 
sprayed with 0.05% primuline
33
, photographed under UV-light and evaluated using GelAnalyzer 
software (http://www.gelanalyzer.com/). 
Active Caspase 3 Assay 
Cells (6x10
5
/flask) attached overnight in media containing 5%FCS or 1%OSE-supplement before 48h-
exposure to ≤0.2% DMSO without/with C75 or G28UCM, trypsinized and counted. 2x10
5
 cells were 
fixed in 2%formaldehyde (15min, room temperature) followed by overnight permeabilization in pure 
methanol at -20°C and immunostaining with phycoerythrin-tagged anti-active caspase 3 (BD 
Pharmingen, San Diego, CA; 3% in 0.1%BSA-buffer) for 30min at room temperature. Data obtained in 
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a BD FACScan were analyzed using ‘Flowing Software 2’ (P. Terho, Turku Centre for Biotechnology, 
Finland). Boundaries between regions H1(viable) and H2(apoptotic) were set at the right slope-base 
of the peak in the histograms of untreated cells labelled with isotype-control antibody and were 
applied to all samples. 
Cell Cycle Analysis 
Cells were treated and harvested as described for active caspase 3 assay. However, instead of 
formaldehyde-fixation, cells were incubated overnight at -20°C in 80%ethanol and then labelled for 
20min at room temperature with propidium iodide (50µg/ml in buffer containing 0.1%TritonX-100, 
0.1mMEDTA and 50µg/mlRNAseA). Stained samples were subjected to flow cytometry and analyzed 
using ModFit-software (Verity Software House, Topsham, ME). Vehicle-treated (≤0.2%DMSO) cells 
were used as control. 
Statistical Analysis 
Student’s t-test or one-way ANOVA followed by Scheffe or Holm-Sidak post-hoc tests. p-Values below 
0.05 were statistically significant. 
Results 
Cultured non-malignant ovarian/oviductal cells express FASN and are growth-arrested by FASN 
inhibitors  
It has repeatedly been shown that non-malignant cells express either no FASN or only very low levels 
of FASN and consequently are not affected by FASN-blockers.
9,18
 However, such a difference in 
cancer versus normal cells has never been demonstrated for the ovarian cell system. Therefore, we 
compared the growth effects of C75 and G28UCM on malignant OC cell lines with those on non-
malignant OSE and fallopian tube secretory epithelial (FT) cells, the two cell types, which are being 
discussed to represent the cells of origin from which most OCs arise.
20,34,35
 The growth-inhibitory 
activity of C75 and G28UCM varied extensively within a panel of 9 OC cell lines with IC50-values 
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ranging from 11-31µM and from 3-25µM, respectively (Figure 1a). The novel FASN-inhibitor G28UCM 
was generally more potent than C75 (p<0.01 for OVCAR-3 and HEY, p<0.001 for all others). Drug-
mediated growth-inhibition and cellular FASN-protein levels revealed a weak but significant inverse 
correlation in OC cells (r=-0.51, p<0.05) corroborating previous findings suggesting that FASN-drug 
sensitivity correlates with target expression.
16,36,37
 For comparison, non-malignant short-lived OSE 
without or with exogenous expression of SV40T/t-antigen – the latter yielding longer-lived cell lines 
IOSE-80, IOSE-364 and IOSE-386 – were exposed to FASN-drugs. Most surprisingly, we observed that 
these non-cancer ovarian cells were exquisitely sensitive to the inhibitors (IC50-values  3-13µM, which 
is discordant with results in other benign cell lines. Similar data were obtained in immortalized FT 
cells (IC50 3–27µM). Correspondingly, all these non-malignant cells contained large amounts of FASN 
as demonstrated by Western blotting (Figure 1b). In contrast, CRL-2522 normal fibroblasts were 
rather resistant against C75 and G28UCM (IC50>48µM and >30µM, respectively) and were essentially 
negative for FASN (Figures 1a,b). Generic C75 is a racemic mixture of (+)- and (-)-enantiomers. 
However, only the (-)-form interferes with FASN-activity.
22
 Consequently, (-)-C75 inhibits growth at 
least as efficiently as the mixture, whereas (+)-C75 lacks efficacy (Figure 1c). This data together with 
the inefficiency of racemic C75 and G28UCM on fibroblasts suggests that non-malignant 
ovarian/oviductal cells are not inhibited due to off-target drug effects. 
Inhibition of FASN in OC causes conversion of membrane-phospholipids (PLs) into storage-lipids 
Conceivably, inhibitors of FASN activity not only block cell growth, but also severely affect cell lipid 
composition. Here, we used SKOV3 (Figure 1d) and OVCAR-3 (Figure 1e) as representative examples 
of OC cells and performed thin-layer chromatography (TLC) separation of lipid extracts for examining 
the effects of C75 and G28UCM on the lipid pattern. Three major neutrallipid classes inluding 
cholesterol esters (CE), triacylglycerols (TAG), and diacylglycerols (DAG) as well as three PL classes 
corresponding to phosphatidylethanolamine (PE), phosphatidylcholine (PC) and sphingomyelin (SM) 
were detected. The relative distribution of these classes was different between both cell lines; DAG, 
PE, PC were equally abundant in SKOV3, whereas in OVCAR-3 PC was predominant, PE was as 
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frequent as in SKOV3, and DAG levels were very low (Figures 1d,e). Generally, after a 72hr-exposure 
to C75, a redistribution of neutrallipids was observed in both cell lines consisting of a decrease of 
DAG and an increase of TAG. At the level of the PLs, decreases of PE and SM were observed in SKOV3 
and a reduction of PC was seen in OVCAR-3 (Figure 1d,e). These redistributions, which were even 
stronger for G28UCM, indicate drug-induced conversion of membrane-PLs into the storage-lipid TAG 
as result of impaired de novo lipogenesis. 
Quiescent normal ovarian/oviductal tissues do not express FASN in vivo 
Sensitivity against FASN-inhibitors and high-level expression of FASN-protein in cultivated non-
malignant ovarian/oviductal cells prompted us to examine FASN-expression in vivo by 
immunostaining formalin-fixed-paraffin-embedded tissues. According to Figure 2, normal human OSE 
lining and FT epithelia reveal no or only very faint cytoplasmic staining, respectively (Figures 2B,D), 
whereas tumor tissues are clearly positive for FASN – albeit with quite different intensities (Figures 
2F,H). Interestingly, immunolabeling of these tissues for the proliferation-associated protein Ki-67 
yielded congruent results: normal OSE was negative (Figure 2A), FT epithelia revealed a few scattered 
nuclei positive for Ki-67 (Figure 2C), OCs with low cytoplasmic staining for FASN contained a small 
fraction of cells with Ki-67 positive nuclei (Figure 2E), whereas OCs with strong FASN labeling were 
also strongly positive for Ki-67 (Figure 2G). Stromal cells were essentially negative for both FASN and 
Ki-67, although, as expected, some scattered adipocytes revealed borderline reactivity with the FASN 
antibody. Collectively, these data suggest that in the ovarian system FASN-expression and hence 
FASN-inhibitor sensitivity are directly related to cell proliferation but not to the oncogenic phenotype 
per se. 
Senescent cultures of ovarian cells are negative for FASN and resistant to FASN inhibitors  
Primary OSE show spontaneous senescence in vitro. Therefore, we wondered whether FASN- 
expression and FASN-drug sensitivity ceases in these cells after prolonged culture. As shown in Figure 
3a, OSE cells cultivated for 22d downregulate FASN while upregulating expression of β-galactosidase 
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– a marker for cell-senescence. Correspondingly, senescent OSE are less responsive to the growth-
inhibitory actions of the FASN-inhibitors (Figure 3b). 
In addition, primary OSE have been transfected with SV40T/t-antigen in order to establish stable, 
immortalized human OSE cell lines (IOSE). However, these cells yet are not fully immortal
21
 and they 
are not tumorigenic. They only reveal prolonged growth activity in vitro, but cell division eventually 
ceases. Accordingly, BrdU-incorporation into synthesized DNA declines and cell multiplication 
diminishes in IOSE-80, IOSE-364 and IOSE-386 during subculture (Figures 3c,d). This is associated with 
expression of SA-β-gal indicating that IOSE cells enter the senescence program during long culture 
periods (Figure 3g, Supplementary Figure 1). Interestingly, resistance against FASN-inhibitors 
gradually increases during cell-senescence, whereas the level of FASN-protein dramatically drops 
(Figures 3e–g) further corroborating that FASN-expression and FASN-drug sensitivity are regulated by 
cell growth activity. 
Using IOSE-80, we next examined the effects of senescence-mediated downregulation of FASN-
expression or of drug-mediated abrogation of FASN-activity on the lipid profile of non-malignant 
ovarian cells. TLC-separation revealed five PL classes including PE, PC, SM, phosphatidylinositol (PI) 
and phosphatidylserine (PS) (Figures 3h,i). Interestingly, in contrast to SKOV3 and OVCAR-3, no 
neutrallipids except DAG were detected in IOSE-80. During cell-senescence we observed an increase 
of PI and SM accompanied by a slight decrease of PE and PC (Figure 3h). On the other hand, a 72hr-
exposure of proliferating IOSE-80 to FASN-inhibitors caused reduction of PI and SM, and upregulation 
of PS and DAG, respectively (Figure 3i). G28UCM again elicited more pronounced effects than C75. 
Downregulation of FASN is dependent on growth arrest but not on cell senescence  
For many years the human OSE has been considered to represent the genuine tissue of origin for 
high-grade  serous OCs, which constitute 60–80% of all human epithelial OCs. During the last decade, 
however, ample evidence challenged this concept and caused a change of paradigm. Accordingly, 
data suggest that both the ovarian surface epithelium and the secretory epithelium of the fallopian 
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tube likely give rise to high-grade serous OC.
20,34,35
 This prompted us to examine FASN-expression and 
FASN-drug sensitivity in immortalized FT cell lines (FT33-TAg, FT237-shp). Although these cells do not 
senesce and do not become positive for SA-β-gal, they yet reveal distinct growth activities with FT33-
TAg showing higher BrdU-labeling and cell multiplication than FT237-shp. This corresponds with the 
level of FASN-protein expression, which is high in the fast-growing FT33-TAg, but much lower in the 
nondividing FT237-shp (Figures 4a–c). Correspondingly, FT33-TAg were more sensitive to inhibition of 
FASN than FT237-shp (Figures 4d,e). These data indicate that silencing of lipogenesis is directly 
related to growth reduction, but is not dependent on cell-senescence. Converesely, upregulation of 
FASN-protein in senescent IOSE-80 (passage24–26) by introduction of FASN (Figure 4f) stimulated 
DNA-replication and cell multiplication as demonstrated by BrdU-incorporation and cell counting 
under the microscope (Figures 4g,h).  
Next, we wondered whether FASN-expression and FASN-drug sensitivity are regulated in a similar 
manner in transformed OC cells. To this end, we took advantage of an OC cell subline system that we 
have previously established. Using density-gradient-centrifugation of the polyclonal parental cell line 
HOC-7 (P) we isolated three monoclonal sublines from the high-density fractions of the gradient (N1–
N3) and three others from the low-density gradient-fractions (D1–D3). HOC-7 parental P-cells and N-
subclones grow significantly faster than the D-subclones (Figure 5a). Overall, the D-phenotype 
reflects a more differentiated functional state.
19,38
 Notably, D-cells express lower levels of FASN-
protein than P- and N-cells and are less sensitive to FASN-inhibitors than P- and N-cells (Figures 5b,c). 
Interestingly, when P- or N-cells are exposed to differentiation inducers like DMSO, they cease 
growth (Figure 5d) and adopt a differentiated state, which is identical to the spontaneous D-
phenotype. Thus, differentiation-inducing chemicals indeed stimulate an endogenous cell maturation 
process rather than just eliciting toxic stress.
27,28
 Ultimately, DMSO-differentiated HOC-7 P-cells 
become senescent as evidenced by the expression of SA-β-gal, downregulate FASN-protein and 
become resistant against inhibition of lipogenesis (Figures 5e,f). 
FASN-inhibitors do not block the cell cycle and do not induce apoptosis in normal ovarian cells 
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Intriguingly, although growth of normal OSE was at least as sensitive against C75 or G28UCM as that 
of immortalized and malignant cells, yet there were substantial differences between these cells. The 
latter commit apoptosis upon FASN-inhibition as shown by occurrence of activated caspase 3 (Figure 
6a, Supplementary Figure 2), of poly(ADP-ribose)polymerase (PARP) cleavage products (Figure 6b) 
and of sub-diploid cell fractions in flow cytometry histograms of propidium iodide-labeled cells (‘sub-
G1-peaks’, Supplementary Figure 3). FASN-drug-treated OSE, however, did not develop any of these 
apoptotic features (Figures 6a,b, Supplementary Figures 2,3), although dose-dependent 
downregulation of full-length PARP1 was yet seen (Figure 6b). Most likely, this effect is caused by 
FASN-drug-induced proteolysis via autophagy as we have previously shown.
37
 In addition, flow 
cytometry of propidium iodide-labelled cells demonstrates that FASN-inhibition induces cell cycle-
arrest in G2/M- and/or S-phases in malignant OC and SV40T/t-transfected IOSE, but not in normal 
OSE, which did not reveal altered cell cycle distribution (Figure 6c, Supplementary Figure 3). Thus, 
FASN-inhibitor-dependent growth-arrest in OSE is mediated by a general attenuation of cell cycle-
progression and not by a particular cell cycle-block or by apoptosis, whereas in immortalized and 
malignant cells growth is abrogated through cell cycle-arrest and apoptosis. This indicates that all cell 
cycle-regulatory mechanisms are functional in normal cells. Interestingly, in the cancer cells the 
balance between drug-induced cell cycle-arrest and apoptosis was variable. SKOV3 cells responded 
primarily by cell cycle-arrest, whereas HOC-7 and OVCAR-3 developed apoptosis (Figures 6a–6c, 
Supplementary Figures 2,3). 
Discussion 
When characterizing the antiproliferative effects of the FASN-inhibitory drugs C75 and G28UCM in 
the OC cell system we observed quite different IC50-values  depending on the particular OC cell line 
tested. We also determined FASN-drug sensitivities in non-malignant OC precursor cells. At present, 
two hypotheses exist regarding the origin of high-grade serous OC, which constitutes 60–80% of all 
epithelial OCs: One favors the OSE lining as tissue of origin, whereas the other considers secretory 
epithelial cells within the fimbriae of the fallopian tube of the oviduct to give rise to the 
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disease.
20,34,35
 Surprisingly, contradictory to the common notion that normal cells are resistant to 
FASN-inhibition due to lack of target expression, non-malignant cells from both tissue sources proved 
at least as sensitive to the drugs as the OC cell lines and were strongly positive for FASN protein. The 
only exception was the fibroblast line CRL-2522, which was negative for FASN and not sensitive to 
FASN-drugs. Thus, this line served as negative control and confirmed that the effects were not due to 
non-specific off-target binding  of the compounds. Generic C75 is composed of (+)- and (-)-
stereoisomers. Recently, Makowski et al.
22
 demonstrated that FASN-inhibition and cancer cell 
growth-arrest is attributed to (-)-C75. Accordingly, we observed growth-inhibition by (-)-C75, but not 
by (+)-C75 further suggesting that the observed antiproliferative activity of FASN-inhibitors on non-
malignant ovarian/oviductal cells is not due to off-target effects. In vitro findings do not always 
correspond with the in vivo situation. Therefore, we wondered whether non-malignant 
ovarian/oviductal tissues are expressing FASN in vivo. Interestingly, immunostaining of tissue 
sections demonstrated that non-malignant cells are indeed negative or only very weakly positive for 
FASN, whereas OC tissues were positive, albeit at quite distinct levels. Thus we wondered whether 
these various levels correlate with the proliferative activity of the tissues. As expected, 
immunostaining for the proliferation marker Ki-67 revealed that FASN-expression is closely 
correlated with cell growth supporting previous clinical data.
11
 Thus, in vivo, normal cells are indeed 
negative for FASN and quiescent, whereas malignant cells are variably positive depending on their 
proliferative activity. It appears therefore that FASN-expression is coupled to cell division rather than 
to the malignant cell phenotype per se. High rates of cell proliferation are a prime goal in cultivating 
cells to provide ample cell material for experimentation. However, primary OSE spontaneously 
reduce growth and become senescent within 3-4 weeks of cultivation. This is accompanied with a 
shut-down of FASN and with occurrence of SA-β-gal, which is a biomarker for the senescence 
process. Concurrently, these senescent cells reveal marked resistance against the FASN-blockers 
when compared to younger OSE. Of note, human OSE transfected with SV40T/t-antigen become 
p53/pRB-deficient and reveal extended life-span. Nevertheless, ultimately they cease growth and 
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become senescent.
21
 Accordingly, after prolonged cultivation these IOSE reduce BrdU-uptake and cell 
proliferation, upregulate SA-β-gal, lose FASN and become resistant against FASN-inhibitors (Figure 3). 
Remarkably, elevating FASN-protein levels in these senescent IOSE cells by introducing wild-type 
FASN-transgene is sufficient to reactivate DNA-synthesis and cell proliferation. We also used fallopian 
tube secretory epithelial cells of the oviduct, which were fully immortalized by eliminating the 
p53/pRB-pathway using either SV40T/t or a p53 shRNA together with mutant CDK4 and by 
introduction of hTERT, the catalytic subunit of telomerase that prevents telomere shortening and 
abrogates replicative senescence yielding immortal but non-tumorigenic FT33-TAg and FT237-shp 
cell lines.
20
 Nonetheless, these cells yet reveal differences in their proliferative activity and were thus 
useful to address the question whether FASN-target expression and sensitivity against FASN-
inhibitors are dependent on the senescence process per se or are only related to cell proliferation. 
Our data demonstrate that slow-growing FT cells have less FASN and are more resistant to FASN-
inhibitors than rapidly growing FT cells supporting the crucial role of cell proliferation for regulation 
of the FASN system, which is in accordance with the slow growth-rate of cultured fibroblasts and 
their lack of FASN and FASN-drug resistance. Thus, it appears that the crucial regulator of FASN is not 
cell-senescence, but cell growth-activity. Moreover, a subclonal cell line system derived from HOC-7 
OC cells comprising three sublines with high/low degrees of growth-activity and cell 
differentiation
19,38
 was characterized by corresponding high/low amounts of FASN-protein and 
high/low sensitivities against FASN-inhibitors, respectively. Finally, we found that the spontaneously 
differentiated cell phenotype can be exogenously induced in parental HOC-7 cancer cells by 
differentiation-inducers. These agents not only reduce growth-activity and cause cell 
differentiation,
27,28
 but also promote cell-senescence and downregulation of FASN and of FASN-drug 
sensitivity. Our data thus indicate that cell growth-activity is the crucial regulator of the FASN system 
not only in normal non-malignant fibroblasts and ovarian/oviductal cells, but also in malignant OC 
cells. Therefore, FASN absence/presence does not directly reflect cell differentiation or senescence 
nor malignant transformation, it only indicates cell growth-activity independent of cell ageing and 
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malignancy. Expression of FASN and sensitivity to FASN-drugs are closely linked to cell growth-
activity and correlate with malignant transformation, cell differentiation or cell senescence only as 
far as these processes are associated with regulation of cell proliferation. Thus, FASN is not strictly a 
marker of malignancy, but rather a marker of cell proliferation. 
Pharmacological blockade of FASN in cancer cells, which controls de novo lipid biosynthesis, will 
naturally affect their lipid-configuration. In both OC models (SKOV3, OVCAR-3), an increase of 
storage-lipids such as TAG at the expense of the PLs – the major membrane lipids – was observed 
upon exposure to FASN-inhibitors. Lipid restocking may represent an adaptive response to enable 
cell survival under conditions of metabolic stress. Minor variabilities in the drug effects on the other 
lipid classes in SKOV3 versus OVCAR-3 may refelect differences in the expression of additional 
lipogenic/lipolytic enzymes in these cells. Interestingly, the lipid pattern of non-malignant ovarian 
surface epithelial cells (IOSE-80) was much less affected by drug-mediated inhibition of FASN-enzyme 
function or by senescence-associated downregulation of FASN-protein when compared to OC cells. 
Moreover, IOSE-80 did not contain the neutral lipids CE and TAG and did not establish TAG-stores 
upon drug-mediated inhibition or senescence-associated downregulation of FASN. These data 
corroborate the notion that the lipid metabolism of non-malignant cells is less dependent on de novo 
lipid synthesis via FASN and that non-malignant cells obtain lipids usually from external sources.
39
 
Notably, there is yet another crucial difference in the biological drug response of normal epithelial 
cells in comparison with cancer cells. In proliferating normal cells, FASN-inhibition only stalls cell 
multiplication without imposing a cell cycle-block or inducing apoptosis. Such a generalized 
deceleration of the cell cycle has previously been observed in polyamine-depleted cell cultures.
40,41
 In 
carcinoma cells, however, blunting FASN heavily affects cell cycle-distribution and causes cell 
extinction by activating apoptotic programs. This difference may be caused by dysfunctional repair- 
and gatekeeper-systems such as the INK4A/Arf/p53/pRb-pathway, which is typically deranged in OC
42
 
or in immortalized precursor cells
20,21
 and thus no longer can protect the cells from metabolic stress-
induced toxicity due to (phospho)lipid deprivation. In the clinical setting, this contrasting behavior of 
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normal and transformed cells upon FASN-blockage may prevent adverse side-effects of FASN-
targeting drugs.  
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Figure Legends 
Figure 1: The effects of FASN-inhibitors C75 and G28UCM on the proliferation, on the expression of 
their target protein FASN and on the lipid class composition of human OC cells and of the 
corresponding non-malignant precursor cells. a) Half-maximal inhibitory concentrations (IC50) of C75 
(left panel) and G28UCM (right panel) in OC cell lines (black columns), normal primary or 
immortalized non-malignant ovarian surface epithelial (OSE, IOSE) cells or immortalized non-
malignant fallopian tube secretory epithelial (FT) cells and in normal human foreskin fibroblasts (CRL-
2522) (gray columns) as obtained with a formazan-dye-assay after 72hr of drug-exposure. b) FASN-
target protein expression in these malignant and non-malignant ovarian/oviductal cells and in 
fibroblasts as demonstrated by Western blotting. α,β-Tubulin was used as loading control. c) 
Immortalized human non-malignant fallopian tube secretory epithelial cells FT237-shp are growth 
inhibited by generic C75 [racemic mixture of (-)- and (+)-enantiomers] and by (-)-C75, but not by (+)-
C75. Formazan-dye-assay after a 72hr-exposure to 25µM drug. d, e) The lipid class composition of 
SKOV3 human OC cells exposed for 72hr to 0.1% DMSO, 40µM C75 or 40µM G28UCM (d) and of 
OVCAR-3 OC cells treated for 72hr with 0.05% DMSO, 20µM C75 or 20µM G28UCM (e) as 
demonstrated by thin-layer chromatography. Individual lipid levels were displayed relative to the 
sum of all lipid classes detected. Means±SD, n≥3. Abbreviations: CE, cholesterol esters; TAG, 
triacylglycerols; DAG, diacylglycerols; PE, phosphatidylethanolamine; PC, phosphatidylcholine; SM, 
sphingomyelin 
Figure 2: Expression of FASN and of the proliferation-associated protein Ki-67 in sections of formalin-
fixed, paraffin-embedded human tissues as demonstrated by immunohistochemistry. Normal non-
malignant human ovarian surface epithelium (A,B) and fallopian tube secretory epithelium (C,D) are 
negative or only very weakly positive for both FASN and Ki-67, respectively, whereas slowly growing 
(E,F) and rapidly growing (G,H) ovarian carcinomas contain moderate or high amounts of FASN and 
Ki-67, respectively. 
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Figure 3: Senescence-mediated downregulation of FASN-protein correlates with upregulation of 
senescence-associated β-glactosidase (β-gal), with reduced sensitivity to FASN-inhibitors, and with 
altered composition of cellular lipid classes in normal and immortalized primary human ovarian 
surface epithelial (OSE) cells as demonstrated by Western blot analysis, formazan-dye cell growth 
assay and thin-layer chromatography, respectively. OSE cells were cultivated for the indicated 
periods of time (7d, 18d, 22d) and then either subjected to Western blotting (a) using antibodies 
against FASN, β-gal or actin (loading control), or exposed for 72hr to various concentrations of 
inhibitors before being examined in a formazan-dye-assay (b). Human OSE engineered to express 
SV40T/t (IOSE) reveal extended life-span, but are not completely immortalized as evidenced by 
reduced DNA-synthesis (c) and cell proliferation (d), elevated resistance to FASN-inhibitors C75 (e) 
and G28UCM (f), downregulation of FASN and upregulation of senescence-associated β-gal (g) upon 
prolonged subculture. IOSE-80, IOSE-364 and IOSE-386 were grown for various numbers of passages 
and were directly labeled with BrdU (c) or with a formazan-dye (d) as described in Materials and 
Methods. Alternatively, at various passages, cells were exposed for 72hr to 15µM C75 (e) or G28UCM 
(f) before being subjected to the formazan-dye-assay. Cells subcultured for various numbers of 
passages were also subjected to Western blotting (g) for detection of FASN (left panel) and β-gal 
(right panel). Actin was used as loading control. Alterations in the lipid class composition between 
proliferating (young) and senescent (old) IOSE-80 (h) and upon 72hr exposure of proliferating IOSE-
80 to 0.03% DMSO, or to IC50-concentrations of C75 (12µM) or G28UCM (5µM) (i) have been 
examined by thin-layer chromatography. Levels of individual lipid classes are displayed relative to the 
sum of all lipid classes detected. Means±SD, n≥3. Abbreviations: PE, phosphatidylethanolamine; PI, 
phosphatidylinositol; PS, phosphatidylserine; PC, phosphatidylcholine; SM, sphingomyelin; DAG, 
diacylglycerols  
Figure 4: Correlation between FASN-expression and cell proliferation in non-malignant 
ovarian/oviductal cells. Individual immortalized non-malignant cell lines obtained from human 
fallopian tube secretory epithelium (FT33-TAg, FT237-shp) express various amounts of FASN, which 
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correlates with DNA-synthesis- and cell proliferation-rate and with resistance to FASN-inhibitors C75 
and G28UCM. a) Proteins (25µg/lane) were electrophoresed and immunoblotted against FASN and 
actin. b,c) Cells labelled with BrdU (b) or a formazan dye (c) were examined for basal DNA-synthesis 
and cell proliferation, respectively. FT33-TAg and FT237-shp cells were also exposed for 72hr to 
20µM C75 (d) or G28UCM (e) and the relative proportion of surviving cells was determined with the 
formazan-dye-assay (details see Materials and Methods). IOSE-80 cells were transfected with 
pcDNA3.1(+) containing or lacking full-length FASN cDNA and transgene expresseion was examined 
by Western blotting. Actin was used as loading control (f). After 48hr, vector- and FASN-transfectant 
cells were labeld with BrdU for DNA-synthesis (g). In addition, after 21d of selection with 300µg/ml 
G418 the cell numbers of polyclonal cultures of vector- and FASN-transfectants were determined 
under the microscope. Means±SD, n=3-6. Statistics in g) and h): **p<0.01 vs. IOSE-80 Vector. 
Student's t-test, two-tailed, unpaired with equal variance. 
Figure 5: Differentiated phenotypes of HOC-7 OC cells are characterized by low levels of FASN, 
upregulation of senescence-associated β-gal, slow growth rate and resistance to FASN-inhibitors.  a) 
Basal cell growth of HOC-7 polyclonal parental P cells, differentiated D- and non-differentiated N-
subclones after 7d of cultivation (formazan-dye-assay). b) Parental cells and subclones were 
subjected to Western blot analysis for expression of FASN. CRL-2552 and OVCAR-3 served as negative 
and positive controls, respectively. Actin was used as loading control. c) Half-maximal inhibitory 
concentrations (IC50) of C75 and G28UCM (72hr treatment) as measure for FASN-drug sensitivity in 
HOC-7 parental cells and D- and N-subclones and d) dose-dependent antiproliferative activity of the 
differentiation-inducer DMSO (72hr exposure) in HOC-7 parental cells (formazan-dye-assay). e) Dose-
dependent downregulation of FASN and upregulation of β-gal by DMSO in HOC-7 parental cells 
(Western blotting). Actin was loading control. f) Pre-exposure of HOC-7 parental cells to DMSO 
induces resistance against FASN-inhibitors. Parental cells were cultured for 72hr in the absence or 
presence of 1.5% (v/v) DMSO and then exposed to 40µM C75 or to 30µM G28UCM in the absence of 
DMSO before determination of relative cell numbers in a formazan-dye-assay. Means±SD, n≥3. 
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Statistics in a) and c): *p<0.05 vs. P, **p<0.01 vs. P, ***p<0.001 vs. P, ANOVA and Scheffe test. 
Statistics in f): ***p < 0.001 of DMSO-differentiated HOC-7 vs. undifferentiated HOC-7. Student's t-
test, two-tailed, unpaired with equal variance. 
Figure 6: The effects of FASN-inhibition by C75 and G28UCM on apoptosis and cell cycle distribution 
in human malignant (SKOV3, HOC-7, OVCAR-3) and non-malignant (IOSE-80, OSE) ovarian epithelial 
cells. a) Percentage of apoptotic cells as determined by flow cytometry detection of intracellular 
active caspase 3 after a 48hr-exposure to vehicle (Control), or to C75 or G28UCM at concentrations 
causing 70–80% growth reduction in formazan-dye-assays, respectively (i.e. 10µM for OSE, 25µM for 
IOSE-80, 30µM for OVCAR-3, 40µM for HOC-7, and 60µM for SKOV3). Means±SD, n=3. b) Dose-
dependent cleavage of PARP1 after a 48hr-exposure to 0–60µM C75 or G28UCM as demonstrated by 
Western blot analysis. β-Actin was loading control. c) Percentage of cells in G0/G1- (upper panel), S- 
(middle panel) or G2/M-phase (lower panel) of the cell cycle after exposure of the cells to the FASN-
inhibitors as determined by flow cytometry of propidium iodide labelled cells. Drug treatment was 
performed as described in a). Means±SD, n=3. One-way ANOVA followed by Holm-Sidak test. 
*p<0.05, **p<0.01, ***p<0.001 of treated vs. control. 
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Fatty acid synthase is a metabolic marker of cell proliferation rather than 
malignancy in ovarian cancer and its precursor cells 
Daniel Veigel1,2*, Renate Wagner1,2*, Gerald Stübiger2,3, Michael Wuczkowski3, Martin Filipits2,4, 
Reinhard Horvat5, Bellinda Benhamú6, María Luz López-Rodríguez6, Asha Leisser1,13, Peter Valent2,7,13, 
Michael Grusch2,4, Fausto G. Hegardt8,9, Jordi García9,10, Dolors Serra8,9, Nelly Auersperg11, Ramón 
Colomer12, Thomas W. Grunt1,2,13 
Supplementary Information 
Supplementary Materials and Methods 
In Situ Staining for Senescence-Associated β-Galactosidase (SA-β-gal) 
SA-β-gal with a pH optimum of 6.0 is a marker for cellular senescence. This senescence-associated 
form of β-galactosidase has recently been shown to be of lysosomal origin.S1 Here we used a β-
galactosidase staining kit from Abnova (Taipei, Taiwan) for detection of this cell ageing marker. IOSE-
80 cells at different stages of senescence (after 15 and 24 passages, corresponding to 10 and 58d in 
continuous culture) were plated in 24 well plates (0.4 and 1.2x104/well) and were grown for 72hr 
before being washed in buffer, fixed and stained overnight at 37°C in a humidified chamber under 
atmospheric CO2 using freshly prepared staining buffer. The procedure was performed according to 
the manufacturer’s (Abnova) protocol except that pH was lowered from 7.2 to 6.0 for staining. Cells 
were then washed and examined under the microscope at ×40 and x100 magnifications. 
Supplementary Reference 
S1. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, Kleijer WJ, DiMaio D, Hwang ES. 
Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 2006; 5: 
187–195. 
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Supplementary Figure Legends 
Supplementary Figure 1: Senescence specific staining of IOSE-80 cells. Low- (left) and high-passage 
(right) IOSE-80 were stained for senescence-associated β-glactosidase (β-gal) as described in 
Supplementary Materials and Methods. The bluish color indicates  β-gal  positive cells. Magnification 
40x (upper) and 100x (lower). 
Supplementary Figure 2: Representative histograms of flow cytometry analyses using active caspase 
3 as a marker for apoptotic cell death after a 48hr-exposure of human malignant (SKOV3, HOC-7, 
OVCAR-3) and non-malignant (IOSE-80, OSE) ovarian epithelial cells to vehicle (Control), or to C75 or 
G28UCM at concentrations causing 70–80% growth reduction in formazan-dye-assays (i.e. 10µM for 
OSE, 25µM for IOSE-80, 30µM for OVCAR-3, 40µM for HOC-7 and 60µM for SKOV3), respectively. 
Regions H1(viable) and H2(apoptotic) were set according to histograms obtained with non-immune 
IgG (not shown).  
Supplementary Figure 3: Representative histograms of flow cytometry analyses after labelling the 
DNA with propidium iodide for determiation of cell cycle distribution subsequent to a 48hr-exposure 
of human malignant (SKOV3, HOC-7, OVCAR-3) and non-malignant (IOSE-80, OSE) ovarian epithelial 
cells to vehicle (Control), or to C75 or G28UCM at concentrations causing 70–80% growth reduction 
in formazan-dye-assays (i.e. 10µM for OSE, 25µM for IOSE-80, 30µM for OVCAR-3, 40µM for HOC-7 
and 60µM for SKOV3), respectively. Data were analyzed using ModFit software. Left red peak G0/G1, 
right red peak G2/M, shaded area S, bluish area dead cells (including ‘sub-G1 peaks’). 
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